DexCom, Inc. (NASDAQ:DXCM) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty ratings firms that are covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $99.00.

A number of equities analysts recently commented on DXCM shares. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a report on Saturday, March 8th. Cfra Research upgraded DexCom to a "hold" rating in a report on Friday, March 21st. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Mizuho initiated coverage on DexCom in a report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. Finally, Citigroup boosted their price objective on DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th.

Insider Buying and Selling at DexCom

In other news, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the transaction, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 105,009 shares of company stock worth $8,044,178 over the last three months. Corporate insiders own 0.32% of the company's stock.

Institutional Trading of DexCom

A number of hedge funds have recently made changes to their positions in DXCM. Norges Bank acquired a new stake in shares of DexCom during the fourth quarter valued at about $385,367,000. Congress Asset Management Co. boosted its stake in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD acquired a new stake in shares of DexCom during the fourth quarter valued at about $96,507,000. Woodline Partners LP acquired a new stake in shares of DexCom during the fourth quarter valued at about $63,338,000. Finally, Northern Trust Corp boosted its stake in shares of DexCom by 22.2% during the fourth quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Performance

DexCom stock traded up $2.52 during midday trading on Friday, reaching $68.85. 695,765 shares of the company's stock were exchanged, compared to its average volume of 4,216,732. DexCom has a 52 week low of $57.52 and a 52 week high of $139.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market cap of $27.00 billion, a price-to-earnings ratio of 48.15, a P/E/G ratio of 2.30 and a beta of 1.50. The stock's 50-day simple moving average is $74.27 and its 200 day simple moving average is $76.66.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts expect that DexCom will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.